既往外照射放疗后前列腺内肿瘤复发患者挽救性立体定向放疗的安全性与疗效:GETUG-AFU 31 研究 1 期结果
本研究为 GETUG-AFU 31 多中心开放标签研究的 1 期部分,评估前列腺癌外照射放疗后生化复发患者接受局灶挽救性立体定向体部放疗(SBRT)的最佳剂量方案。21 例患者接受 6 Gy×5 或 6 Gy×6 分次治疗,其中 12 例接受 6 Gy×6 剂量水平,未观察到剂量限制性毒性。中位随访 12.3 个月,晚期 2 级泌尿生殖毒性累积发生率为 41.2%(95%CI 18.1-63.1%),无>2 级泌尿生殖毒性及≥2 级胃肠道毒性,所有患者末次随访时存活且无复发。作者为后续 2 期研究选择 6 Gy×6 方案。
要点
- 21 例前列腺癌放疗后局部复发患者接受挽救性 SBRT,12 例在 6 Gy×6 剂量水平,未观察到剂量限制性毒性。
- 急性 2 级泌尿生殖毒性发生率为 19%,晚期 2 级泌尿生殖毒性累积发生率为 41.2%(95%CI 18.1-63.1%)。
- 无>2 级泌尿生殖毒性及≥2 级胃肠道毒性,中位随访 12.3 个月时全部患者存活且无复发。
核心结论
- 作者为后续 2 期挽救性 SBRT 研究选择了 6 Gy×6 分次剂量方案;在较短随访期内,毒性水平似乎可接受。
研究设计与样本
- GETUG-AFU 31 多中心开放标签研究的 1 期部分,采用时间-事件连续重新评估法选择剂量方案。
- 主要入选标准为组织学证实的生化复发、复发时临床分期 T1-T2、有多参数磁共振成像数据、挽救性 SBRT 前前列腺特异性抗原(PSA)≤10 ng/ml、PSA 倍增时间>10 个月、国际前列腺症状评分≤12。
- 21 例患者接受局灶 SBRT 5 或 6 分次、每次 6 Gy 治疗,其中 12 例在 6 Gy×6 剂量水平;中位(四分位距)年龄 76.8 岁(72.2-80.8)。
主要发现
- 未观察到剂量限制性毒性;剂量限制性毒性定义为治疗开始后前 18 周内发生的≥3 级胃肠道或泌尿生殖道毒性,或任何 4 级毒性(依据美国国家癌症研究所不良事件通用术语标准 4.03 版)。
- 急性 2 级泌尿生殖道毒性发生率为 19%。
- 中位随访 12.3 个月时,晚期 2 级泌尿生殖毒性估计累积发生率为 41.2%(95%CI 18.1-63.1%)。
- 未报告>2 级泌尿生殖毒性和≥2 级胃肠道毒性;所有接受治疗的患者在末次随访时均存活且无复发。
临床怎么用
- 作者为后续 2 期挽救性 SBRT 研究选择了 6 Gy×6 分次剂量方案。
- 作者认为在较短随访期内,该挽救性 SBRT 方案的毒性水平似乎可接受。
局限性
- 原文报告随访时间短(中位随访 12.3 个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus on the best local salvage treatment for prostate cancer recurrence after primary external beam radiotherapy. Prospective data on stereotactic body radiation therapy (SBRT) are very scarce. OBJECTIVE: To determine the optimal dose regimen for salvage SBRT. DESIGN, SETTING, AND PARTICIPANTS: The present report concerns the phase 1 part of the GETUG-AFU 31 multicenter open-label study. The main inclusion criteria were histologically proven biochemical recurrence, clinical stage T1-T2 upon relapse, multiparametric magnetic resonance imaging data, prostate-specific antigen (PSA) level ≤10 ng/ml prior to salvage SBRT, PSA doubling time >10 mo, and an International Prostate Symptom Score of ≤12. INTERVENTION: Five or six fractions of 6 Gy were delivered using focal SBRT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Dose-limiting toxicity (DLT) was defined as grade ≥3 gastrointestinal or genitourinary tract toxicity, or any grade 4 toxicity (according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03) occurring in the first 18 wk following treatment initiation. A time-to-event continual reassessment method was used to select the dose regimen. RESULTS AND LIMITATIONS: Twenty-one patients were treated (median [interquartile range] age: 76.8 yr [72.2-80.8]), including 12 at 6 × 6 dose level. No DLT was observed. The acute grade 2 genitourinary tract toxicity rate was 19%. With a median follow-up of 12.3 mo, the estimated cumulative incidence of late grade 2 genitourinary toxicity was 41.2% (95% confidence interval: 18.1-63.1%). No grade >2 genitourinary toxicity and no grade ≥2 gastrointestinal toxicity were reported. All treated patients were alive and relapse free at the last follow-up. CONCLUSIONS: A 6 × 6 Gy dose regimen was selected for our phase 2 study of salvage SBRT. With a short follow-up period, the level of toxicity appears to be acceptable. PATIENT SUMMARY: There is no consensus on the best local treatment for patients with local relapse after radiotherapy for prostate cancer. Prospective data are very scarce. Our early phase trial allowed us to recommend six fractions of 6 Gy using high-precision radiotherapy for further studies.
引用
- Pasquier D, Lacornerie T, Supiot S, et al. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study. Eur Urol Oncol. 2023. PMID: 36754722. doi:10.1016/j.euo.2023.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。